JP2006514607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514607A5 JP2006514607A5 JP2004523679A JP2004523679A JP2006514607A5 JP 2006514607 A5 JP2006514607 A5 JP 2006514607A5 JP 2004523679 A JP2004523679 A JP 2004523679A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2006514607 A5 JP2006514607 A5 JP 2006514607A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- ala
- arg
- lys
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 31
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 18
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000012503 blood component Substances 0.000 claims 10
- 239000003937 drug carrier Substances 0.000 claims 9
- -1 methylamino, hydroxyethyl Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 230000000903 blocking effect Effects 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- JJVJPJWQXDQCEI-UHFFFAOYSA-N ethenylhydrazine Chemical group NNC=C JJVJPJWQXDQCEI-UHFFFAOYSA-N 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 2
- 102000004571 Natriuretic peptide Human genes 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 239000000692 natriuretic peptide Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40019902P | 2002-07-31 | 2002-07-31 | |
| US40041302P | 2002-07-31 | 2002-07-31 | |
| PCT/CA2003/001097 WO2004011498A2 (en) | 2002-07-31 | 2003-07-29 | Long lasting natriuretic peptide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009273992A Division JP2010047614A (ja) | 2002-07-31 | 2009-12-01 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514607A JP2006514607A (ja) | 2006-05-11 |
| JP2006514607A5 true JP2006514607A5 (enExample) | 2006-09-07 |
Family
ID=31191354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523679A Pending JP2006514607A (ja) | 2002-07-31 | 2003-07-29 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
| JP2009273992A Pending JP2010047614A (ja) | 2002-07-31 | 2009-12-01 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009273992A Pending JP2010047614A (ja) | 2002-07-31 | 2009-12-01 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1530588A2 (enExample) |
| JP (2) | JP2006514607A (enExample) |
| AU (1) | AU2003246500A1 (enExample) |
| CA (1) | CA2488348A1 (enExample) |
| WO (1) | WO2004011498A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| CA2436399A1 (en) | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| AU2003268531A1 (en) | 2002-09-06 | 2004-03-29 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| US7648962B2 (en) | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| AU2005227870A1 (en) | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| PL2348114T3 (pl) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
| ATE496060T1 (de) | 2004-07-15 | 2011-02-15 | Univ Queensland | Proteinartige verbindungen und anwendungen davon |
| JP2008537542A (ja) * | 2005-03-07 | 2008-09-18 | モンドビーオテッヒ ライセンシング オアト アーゲー | アビプタジルのための処方物 |
| WO2006108686A2 (en) * | 2005-04-14 | 2006-10-19 | Aic | Bnp agonists |
| WO2007041645A2 (en) * | 2005-10-03 | 2007-04-12 | Scios Inc. | Oxidized human bnp |
| WO2007127487A2 (en) | 2006-04-28 | 2007-11-08 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
| JP5010913B2 (ja) * | 2006-12-31 | 2012-08-29 | 寿子 小出 | 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法 |
| KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| AP2009005091A0 (en) | 2007-07-06 | 2009-12-31 | Theratechnologies Inc | Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (ALPHA-MSH) and atrial natriuretic protein (ANP) and uses in hypertension andacute kidney injury |
| DE102010032482A1 (de) | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung |
| WO2012013597A1 (de) | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren |
| EP2658979B1 (en) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| SG192744A1 (en) * | 2011-02-23 | 2013-09-30 | Madeleine Pharmaceuticals Pty Ltd | Therapeutic method for treating congestive heart failure |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| CN102286092B (zh) | 2011-09-14 | 2014-01-01 | 深圳翰宇药业股份有限公司 | 利拉鲁肽的固相合成方法 |
| EP2849567B1 (en) | 2012-05-17 | 2022-03-23 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| JP6946182B2 (ja) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ | 治療用ビタミンｄコンジュゲート |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| TW201708247A (zh) * | 2015-05-29 | 2017-03-01 | Igisu Co Ltd | 環狀胜肽及含該環狀胜肽之藥物、外用劑及化粧品 |
| KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
| WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| CA3019726A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
| WO2018035420A1 (en) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| JP2020512363A (ja) | 2017-03-31 | 2020-04-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| JP2023504208A (ja) | 2019-12-09 | 2023-02-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼポリペプチド及びその使用方法 |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| JP2025534350A (ja) | 2022-09-30 | 2025-10-15 | エクステンド バイオサイエンシズ インコーポレーテッド | 長時間作用型副甲状腺ホルモン |
| AU2023364177A1 (en) | 2022-10-21 | 2025-05-01 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
| CN116284329B (zh) * | 2023-04-28 | 2023-12-08 | 成都奥达生物科技有限公司 | 一种长效利钠肽化合物 |
| CN119529033A (zh) * | 2024-12-02 | 2025-02-28 | 中山大学 | 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU597919B2 (en) * | 1985-11-05 | 1990-06-14 | Scios Nova Inc. | Analogs of atrial natriuretic peptides |
| JP3042782B2 (ja) * | 1985-11-05 | 2000-05-22 | サイオス インコーポレイテッド | 心房性ナトリウム尿排泄亢進ペプチド類似化合物 |
| AU5827690A (en) * | 1989-05-24 | 1990-12-18 | Abbott Laboratories | Atrial peptide derivatives |
| CN101289500A (zh) * | 1999-05-17 | 2008-10-22 | 康久化学生物技术公司 | 病毒感染的长效融合肽抑制剂 |
| SI1105409T1 (sl) * | 1999-05-17 | 2006-06-30 | Conjuchem Inc | Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente |
| JP2003508501A (ja) * | 1999-09-07 | 2003-03-04 | コンジュケム，インコーポレーテッド | 生物学的結合のための肺送達 |
-
2003
- 2003-07-29 CA CA002488348A patent/CA2488348A1/en not_active Abandoned
- 2003-07-29 WO PCT/CA2003/001097 patent/WO2004011498A2/en not_active Ceased
- 2003-07-29 EP EP03771007A patent/EP1530588A2/en not_active Ceased
- 2003-07-29 JP JP2004523679A patent/JP2006514607A/ja active Pending
- 2003-07-29 AU AU2003246500A patent/AU2003246500A1/en not_active Abandoned
-
2009
- 2009-12-01 JP JP2009273992A patent/JP2010047614A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514607A5 (enExample) | ||
| JP4175668B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| JP6069441B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| AU2009280021B2 (en) | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal | |
| AU672589B2 (en) | Novel amylin antagonist peptides and uses therefor | |
| JP2020502051A5 (enExample) | ||
| KR100905380B1 (ko) | 신경펩타이드-2 수용체(ｙ２ｒ) 작용물질 활성을 갖는펩타이드 | |
| AU638423B2 (en) | Therapeutic peptides | |
| JP2012530145A5 (enExample) | ||
| US20080194486A1 (en) | Novel Anti-Obesity Agents | |
| JP2011511753A5 (enExample) | ||
| CA2488348A1 (en) | Long lasting natriuretic peptide derivatives | |
| JP2017535527A5 (enExample) | ||
| KR20110125235A (ko) | 뉴로펩타이드 ｙ 수용체 결합성 화합물을 포함하는 세포독성 접합체 | |
| TW202317604A (zh) | 用於治療遺傳性血鐵沉積症之鐵調素模擬物 | |
| ES2988026T3 (es) | Agonistas del receptor CRF2 y su uso en terapia | |
| CN102532301A (zh) | 一类新型的Exendin-4类似物及其制备方法 | |
| ES2360598T3 (es) | Receptores de linfocitos t que se unen especificamente a vygfvracl-hla-a24. | |
| JPWO2020120983A5 (enExample) | ||
| JP6046060B2 (ja) | エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 | |
| JP2003500341A5 (enExample) | ||
| TW202231655A (zh) | 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶 | |
| WO2019204402A1 (en) | Compositions and methods for treatment of cancer | |
| CN117480176A (zh) | 用于治疗遗传性血色病的铁调素模拟物 | |
| US11149064B2 (en) | Vasoactive polypeptides for smooth muscle relaxation |